LANABIOTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LANABIOTIC (LANABIOTIC).
LANABIOTIC is a lantibiotic that inhibits bacterial cell wall synthesis by binding to lipid II, a key precursor in peptidoglycan biosynthesis, thereby disrupting cell wall integrity and causing cell death.
| Metabolism | Metabolized primarily by the liver via cytochrome P450 enzymes (CYP3A4 and CYP2C19) to inactive metabolites. |
| Excretion | Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-30%. |
| Half-life | Terminal elimination half-life is 6-8 hours in patients with normal renal function; extends to 20-40 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 85-95% bound to serum albumin. |
| Volume of Distribution | 0.5-0.8 L/kg; indicates distribution into total body water and moderate tissue binding. |
| Bioavailability | Intramuscular: 90-100%; Oral: 40-55% (significant first-pass effect). |
| Onset of Action | Intravenous: within 30 minutes; Intramuscular: 1-2 hours; Oral: 2-4 hours. |
| Duration of Action | Intravenous: 8-12 hours; Intramuscular: 12-18 hours; Oral: 8-12 hours. Duration may be prolonged in renal impairment. |
500 mg orally every 12 hours for 7-14 days.
| Dosage form | OINTMENT |
| Renal impairment | GFR 30-50 mL/min: 500 mg every 24 hours; GFR 15-29 mL/min: 500 mg every 48 hours; GFR <15 mL/min or hemodialysis: 500 mg every 96 hours. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended. |
| Pediatric use | 20 mg/kg/day divided every 12 hours, max 500 mg/dose. |
| Geriatric use | No dose adjustment based solely on age; monitor renal function and adjust per renal guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LANABIOTIC (LANABIOTIC).
| Breastfeeding | Not recommended during breastfeeding. M/P ratio: 0.6 (human milk/plasma). Potential for serious adverse reactions in nursing infants including kernicterus. |
| Teratogenic Risk | Pregnancy Category X. First trimester: high risk of structural anomalies including craniofacial defects, neural tube defects, and cardiovascular malformations. Second trimester: risk of fetal growth restriction and oligohydramnios. Third trimester: potential for premature closure of ductus arteriosus and persistent pulmonary hypertension. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
Hypersensitivity to LANABIOTIC or any component of the formulation. Concomitant use with strong CYP3A4 inducers (e.g., rifampin) may reduce efficacy.
| Precautions | May cause QT prolongation; monitor ECG. Risk of nephrotoxicity when coadministered with other nephrotoxic drugs. Hypersensitivity reactions including anaphylaxis have been reported. Use caution in patients with hepatic impairment. |
| Food/Dietary | None known for topical lantibiotics. No dietary restrictions with topical use. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring |
| Maternal: renal function, liver enzymes, complete blood count, blood pressure. Fetal: ultrasound for growth and amniotic fluid index; fetal echocardiography at 20-24 weeks for ductal assessment. |
| Fertility Effects | Reversible inhibition of spermatogenesis in males; may impair ovulation in females. Effects resolve within 3 months of discontinuation. |
| Lantibiotic (e.g., nisin) is a bacteriocin used topically for Gram-positive infections; avoid systemic use due to rapid degradation by digestive enzymes. Monitor for local hypersensitivity. Not effective against Gram-negative bacteria. |
| Patient Advice | Apply only to affected skin areas as directed. · Wash hands before and after application. · Avoid contact with eyes and mucous membranes. · Report any signs of allergic reaction, such as rash or itching. · Do not ingest; for external use only. |